nach oben

Erschienen in:

13.12.2017 | Original Article

Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients

verfasst von: L. K. Schoch, A. Asiama, M. Zahurak, S. Shanbhag, J. Hurtt, K. Sawyer, L. J. Swinnen, N. Wagner-Johnston, R. J. Jones, R. F. Ambinder, Douglas E. Gladstone

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Everolimus, an mTOR inhibitor, is active in refractory lymphomas. However, toxicity with flat dosing limits its usage. Speculatively, pharmacokinetically-targeted dosing could improve tolerability. Therefore, we studied serum-trough dosing with rituximab as maintenance after high-dose cyclophosphamide (HDC) consolidation in lymphoma patients.

Patients/methods

After HDC, everolimus was dosed to serum trough levels (goal 3–15 ng/mL), with quarterly rituximab infusions for 1 year while maintaining < grade II non-hematologic and < grade III hematologic toxicities. Adult patients in first PR/CR with: mantle cell, transformed, double-hit, or high risk chronic lymphocytic leukemia or in second PR for any relapsed B cell lymphoma were eligible. Prophylaxis was given for encapsulated organisms, HSV and PCP. Serum IgG levels were maintained > 500 mg/dL.

Results

49 patients, median age: 59.0 years enrolled; MCL (26), CLL (10), transformed lymphoma (7), and other histologies (6). During the life of the study, the most frequent everolimus dosing has been 2.5 mg daily or 2.5 mg every other day; at these doses, serum levels are within the therapeutic range and non-hematologic toxicity is rare. At a median follow-up of 27.1 months, three patients remain on active therapy. Two patients withdrew secondary to potentially-attributable adverse events including a bacterial pneumonia and a viral pneumonia; this low rate of discontinuation compares well to other long-term everolimus trials. While a 58 and 76% EFS at 30 months for the entire cohort and MCL cohort, respectively, compares similarly to previously published HDC/rituximab data, longer follow-up is required.

Conclusions

Pharmacokinetically-targeted dosing appears to increase everolimus tolerability. This finding may be applicable to other patient populations.

Nur mit Berechtigung zugänglich

Petroulakis E, Mamane Y, Le Bacquer O et al (2007) mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 96:R11–R15CrossRefPubMed

Hartford CM, Ratain MJ (2007) Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 82:381–388CrossRefPubMed

Wang M, Popplewell LL, Collins RH Jr et al (2014) Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol 165:510–518CrossRefPubMed

Conconi A, Raderer M, Franceschetti S et al (2014) Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. Br J Haematol 166:69–76CrossRefPubMed

Witzig TE, Reeder CB, LaPlant BR et al (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25:341–347CrossRefPubMed

Yardley DA, Bosserman LD, O’Shaughnessy JA et al (2015) Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute. Breast Cancer Res Treat 154:89–97CrossRefPubMed

Kirchner GI, Meier-Wiedenbach I, Manns MP (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43:83–95CrossRefPubMed

Yee KW, Zeng Z, Konopleva M et al (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12:5165–5173CrossRefPubMed

Shipkova M, Hesselink DA, Holt DW et al (2016) Therapeutic Drug monitoring of everolimus: a consensus report. Ther Drug Monit 38:143–169CrossRefPubMed

10.

Gladstone DE, Bolanos-Meade J, Huff CA et al (2011) High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma 52:2076–2081CrossRefPubMedPubMedCentral

11.

Wanner K, Hipp S, Oelsner M et al (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134:475–484CrossRefPubMed

12.

Haritunians T, Mori A, O’Kelly J et al (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21:333–339CrossRefPubMed

13.

Yu B, DiBussolo J, Van Natta K, Kozak M (2014) Quantitation of immunosuppressant drugs in whole blood using the prelude-SPLC system and TSQ endura mass spectrometer for reasearch. https://assets.thermofisher.com/TFS-Assets/CMD/Application-Notes/AN-64043-Immunosupressants-Whole-Blood-AN604-EN-HR.pdf. Accessed 1 Oct 2017

14.

Novartis (2016) Affinitor (everolimus) tablets prescribing information. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/afinitor.pdf. Accessed 1 Oct 2017

15.

Nitta E, Izutsu K, Sato T et al (2007) A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 18:364–369CrossRefPubMed

16.

Tesfa D, Palmblad J (2011) Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 4:619–625CrossRefPubMed

17.

Kim SJ, Shin DY, Kim JS et al (2016) A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Ann Oncol 27:712–718CrossRefPubMed

18.

Ghobrial IM, Redd R, Armand P et al (2015) Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia 29:2338–2346CrossRefPubMed

19.

McRee AJ, Davies JM, Sanoff HG et al (2014) A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Cancer Chemother Pharmacol 74:117–123CrossRefPubMedPubMedCentral

20.

Kanesvaran R, Watt K, Turnbull JD et al (2015) A Single-Arm Phase 1b Study of everolimus and sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 13:319–327CrossRefPubMed

21.

Witzig TE, Reeder C, Han JJ et al (2015) The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood 126:328–335CrossRefPubMedPubMedCentral

22.

Powles T, Wheater M, Din O et al (2016) A Randomised Phase 2 Study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. Eur Urol 69:450–456CrossRefPubMed

23.

Rugo HS, Pritchard KI, Gnant M et al (2014) Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 25:808–815CrossRefPubMedPubMedCentral

24.

Motzer RJ, Alyasova A, Ye D et al (2016) Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol 27:441–448CrossRefPubMed

25.

Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968–977CrossRefPubMed

26.

Hurvitz SA, Andre F, Jiang Z et al (2015) Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 16:816–829CrossRefPubMed

27.

Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813CrossRefPubMedPubMedCentral

28.

Choueiri TK, Escudier B, Powles T et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814–1823CrossRefPubMedPubMedCentral

29.

Witzig TE, Tobinai K, Rigacci L et al (2016) PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 34:7506–7506

30.

Duran I, Goebell PJ, Papazisis K et al (2014) Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf 13:361–372CrossRefPubMed

31.

Deppenweiler M, Falkowski S, Saint-Marcoux F et al (2017) Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharmacol Res 121:138–144CrossRefPubMed

32.

Laborde L, Oz F, Ristov M et al (2017) Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer. Cancer Chemother Pharmacol 80(4):869–878CrossRefPubMed

Titel: Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients
verfasst von: L. K. Schoch
A. Asiama
M. Zahurak
S. Shanbhag
J. Hurtt
K. Sawyer
L. J. Swinnen
N. Wagner-Johnston
R. J. Jones
R. F. Ambinder
Douglas E. Gladstone
Publikationsdatum: 13.12.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2018
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3499-y

Springer Medizin

Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients